Quantum Protein Simulation Gordon Bell Finalist
Analysis based on 11 articles · First reported Jul 20, 2026 · Last updated Sep 09, 2026
This breakthrough enhances IBM's leadership in quantum computing, potentially boosting its competitive position and stock sentiment. It also signals progress in applying quantum computing to drug discovery, which could accelerate pharmaceutical R&D and create long-term value for the healthcare sector.
A multidisciplinary team from Cleveland Clinic, Riken, and IBM has been named a finalist for the 2026 ACM Gordon Bell Prize for simulating the largest biologically meaningful molecules ever modeled with quantum computers, reaching a scale of 12,635 atoms. The team combined quantum and classical computing methods in a framework called quantum-centric supercomputing. Using IBM Quantum Heron processors at Cleveland Clinic and Riken, alongside supercomputers Fugaku and Miyabi-G, they calculated the electronic structure of two large protein complexes. The work, initially published in May 2026, demonstrated the first-known simulation of a 303-atom protein with quantum computers, then scaled the method roughly 40 times with a 210-fold improvement in accuracy. Updated results in September 2026 further improved binding energy accuracy. The team also validated the workflow on Riken's new ROQUO supercomputer, reducing manual operations and errors. The winner will be announced at SC26 in November 2026. This research, supported by Japan — New Energy and Industrial Technology Development Organization and Japan's METI, advances drug discovery by improving predictions of how medicines interact with protein targets.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard